HPV Viral Test for Primary Cervical Cancer Screening at the Nabil Choucair Health Center in Senegalese Women 30 to 65 Years Old

The objective of this study was to describe demographics of patients who had benefited from a cervical cancer screening by an HPV viral test; to specify the protocol used to establish diagnosis using the test results; and to describe treatment and follow-up methods on positively tested patients. This was an descriptive prospective cohort study conducted at the Nabil Choucair health center and the Military Hospital of Ouakam from May 1st 2017 to January 30th 2018. The study involved 144 patients who had benefited from an HPV ABBOOT m2000 viral test. The studied parameters included socio-demographic characteristics, clinical aspects, test results, diagnosis, treatment and follow-up. The data was collected on a form and the statistical analysis was performed using Epi-info 7. In this study we collected 144 women. The mean age of the patients was 39.9 years. Patients were predominantly married (84%) and mostly housewives (48.1%), with slightly more than half (55.6%) of them who attended school. More than half of the patients 61.8% were under contraception. Almost all patients (92.4%) were of child bearing age. The average gravidity was 3.4 with an average parity of 2.7. The average age at marriage was 22.6 years mostly in a monogamous household (56.8%). The average age at first intercourse was 22.1. The average age at first pregnancy was 23.9. More than ¾ of women (78.3%) had one partner; however, note that 21.7% of the patients had 2 or more partners. The viral test was positive in 17 patients (11.8%). Papillomaviruses 16 and 18 were the most encountered (56%). Colposcopy was normal and satisfactory in 9 patients (53%), 2 patients had abnormal minor changes (11.7%) and 2 cases had major changes (11.7%). Cervical biopsy was performed in 2 patients (11.7%), histology showed CIN3 and micro invasive carcinoma. For those patients a conization was performed. The postoperative course was simple. The HPV viral test for primary cervical cancer screening offers opportunities and is possible in developing countries such as Senegal despite its limited means.